Phase 1 Depression and Anxiety Trial, Recruiting NCT06671977 Sponsor: Deepak C. D'Souza Condition: Depression and Anxiety
Back to Depression And Anxiety

Phase 1 Depression and Anxiety Trial, Recruiting

NCT06671977
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Men and women between the ages of 21 and 65
  • People with a body weight considered in the healthy to moderately overweight range (BMI between 18 and 35)
  • People willing to avoid taking any medications not approved by the study doctor during the trial
  • People willing to avoid alcohol and recreational drugs during the trial
  • People who return a negative drug test result
  • People willing and able to avoid smoking during each test session
  • Women who are able to become pregnant and are sexually active must be willing to use an effective form of contraception
  • People willing to arrange transport to and from testing sessions rather than driving themselves

For people with Major Depressive Disorder (MDD), these additional criteria apply:

  • People who have been diagnosed with Major Depressive Disorder
  • People who have not had a satisfactory response to antidepressant medications
  • People either currently receiving treatment for depression from a clinician and willing to continue that treatment throughout the study, or people not currently in treatment
  • People willing to allow the research team to communicate with their mental health provider
  • People whose mental health clinician supports their participation in the trial

For healthy volunteers, these additional criteria apply:

  • People with no current psychiatric disorder (excluding nicotine or caffeine use)
  • People who have not taken psychiatric medication for more than 3 months at any point in their life

Who may not be able to join:

  • People taking medications that could significantly interfere with the study medications
  • People with cognitive difficulties that could affect their ability to participate
  • People with an alcohol or substance use disorder
  • People with any history of a hallucinogen use disorder
  • People who regularly use or have misused hallucinogens
  • People with a history of bad reactions to drugs that alter perception
  • People with significant blood pressure problems
  • People who are pregnant or currently breastfeeding
  • People with unstable medical conditions
  • People with significant heart or cardiovascular disease
  • People with significantly abnormal laboratory test results
  • People with a history of serotonin syndrome (a serious reaction involving certain medications)

For people with MDD, these additional exclusions apply:

  • People whose primary psychiatric diagnosis is something other than MDD
  • People with a medical condition that would make participation unsuitable (confirm with trial site)

For healthy volunteers, these additional exclusions apply:

  • People who currently have a psychiatric disorder (excluding nicotine or caffeine use)
  • People with a close family history of serious mental illness such as schizophrenia or bipolar disorder

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 15 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Deepak D'Souza, MD, Yale University

Phone: (203) 932-5711

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Deepak C. D'Souza
Registry
ClinicalTrials.gov
Start date
14 March 2025
Est. completion
1 December 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Safety of Physiological indices; Psychedelic Effects; Psychotomimetic Effects; Anxiety; Depression; Intensity of the Experience; Drug Reinforcing Effects; Tolerability of Overt Adverse Effects; Electrophysiological

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov